Grey Wolf Therapeutics Funding: $131M Raised, Series B
Grey Wolf Therapeutics is based in Oxford, United Kingdom. It has raised $131M in total funding. Latest round: Series B.
Grey Wolf Therapeutics funding overview
Grey Wolf Therapeutics is based in Oxford, United Kingdom. Grey Wolf Therapeutics has raised $131M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in May 2024. The round record for Grey Wolf Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include ICG, Pfizer Ventures, Andera Partners, Canaan, Earlybird Venture Capital, Oxford Science Enterprises and 1 others. 7 distinct backers are named across the disclosed rounds.
Grey Wolf Therapeutics at a glance
Total raised
$131M
Latest round
Series B
Latest round date
May 2024
Headquarters
Oxford, United Kingdom
Notable investors
ICG, Pfizer Ventures, Andera Partners, Canaan, Earlybird Venture Capital, Oxford Science Enterprises, British Patient Capital
Frequently asked about Grey Wolf Therapeutics funding
How much has Grey Wolf Therapeutics raised?
Grey Wolf Therapeutics has raised $131M in total disclosed funding across the rounds on record.
Who has invested in Grey Wolf Therapeutics?
ICG, Pfizer Ventures, Andera Partners, Canaan, Earlybird Venture Capital, Oxford Science Enterprises are named among the investors backing Grey Wolf Therapeutics.
What was the latest Grey Wolf Therapeutics funding round?
The most recent disclosed round is a Series B, announced in May 2024.
Where is Grey Wolf Therapeutics based?
Grey Wolf Therapeutics is based in Oxford, United Kingdom.
When did Grey Wolf Therapeutics last raise?
The last disclosed Grey Wolf Therapeutics round closed in May 2024 at Series B.
Totals shown for Grey Wolf Therapeutics aggregate every disclosed round on file. To see how that compares, browse the companies in Oxford and the investors behind them below.
